Table 1.
Clinical characteristics of the discovery cohort. Values represent median ± standard deviation
| Discovery cohort | All patients (n=14) | Crohn’s disease (n=4) | Ulcerative colitis (n=10) | Range | ||
|---|---|---|---|---|---|---|
| Age (y) | 38.6 ± 13.6 | 32.3 ± 14.6 | 38 ± 11.8 | 16–62 | ||
| BMI | 26.5 ± 6.8 | 27 ± 8.6 | 27 ± 7.1 | 19.7–38.9 | ||
| Female sex, n (%) | 7 (50%) | 3 (75%) | 4 (40%) | |||
| Time since diagnosis, y | 14 ± 11 | 12 ± 6 | 16.1 ± 12 | 6–46 | ||
| Smokers, n (%) | 3 (21.4%) | 1 (25%) | 2 (20%) | |||
| Prednisolone >20mg/day, n (%) | 2 (14.3%) | 1 (25%) | 1 (10%) | |||
| Budesonide, n (%) | 1 (7.1%) | 0 | 1 (10%) | |||
| Thiopurines, n (%) | 3 (21.4%) | 1 (25%) | 2 (20%) | |||
| Mesalamine therapy, n (%) | 12 (85.7%) | 2 (50%) | 9 (90%) | |||
| Clinical remission at week 14, n (%) | 7 (50%) | 3 (75%) | 4 (40%) | |||
| Remitters (R)/non-remitters (NR) | R | NR | R | NR | ||
| C-reactive protein, baseline | 15.1±16.3 | 12.0 | 9.3±9.2 | 17.1±7.7 | ||
| C-reactive protein, week 2 | 4.1±3.5 | 3.6 | 2.6±3.1 | 13.8±12.2 | ||
| C-reactive protein, week 6 | 5.4±3.5 | 5.4 | 7.2±13.0 | 6.4±7.8 | ||
| C-reactive protein, week 14 | 8.6±3.7 | 4.8 | 3.0±8.0 | 8.3±12.6 | ||
| HBI/pMAYO score, baseline | 7±1 | 12 | 5.5±2.4 | 6±1.1 | ||
| HBI/pMAYO score, week 2 | 6±0.6 | 12 | 3±2.4 | 5±1.8 | ||
| HBI/pMAYO score, week 6 | 3±2.1 | 12 | 2.5±1.1 | 6±2.2 | ||
| HBI/pMAYO score, week 14 | 1±2.1 | 12 | 0.75±0.9 | 6±1.2 | ||